Novavax (NVAX) closed at $6.36 in the latest trading session, marking a -2.15% move from the prior day. This move lagged the S&P 500's daily gain of 0.52%. On the other hand, the Dow registered a gain ...

Here’s a look at what Robert F. Kennedy Jr. has said and done since becoming the nation’s top health official on Feb. 13.

Retail investor chatter around vaccine makers Novavax, Moderna, and Pfizer rose on Wednesday, ahead of a closely watched CDC ...

Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval ...

FDA authorizes protein-based COVID vaccine by Novavax 03:24. The Biden administration is warning states to prepare for a "limited supply" of Novavax's COVID-19 vaccine to be made available, after ...

And the Novavax Covid-19 vaccine that just got emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) is certainly new. It’s new in that it’s not completely new.

Novavax’s protein-based vaccine is the latest FDA-authorized COVID booster available this fall. Here’s what you should know. Skip to main content. Scientific American. October 16, 2023.

Novavax COVID vaccine will still save lives, experts say, even with limited supply. There are still more than 26 million American adults who are unvaccinated.

The Novavax vaccine targets the same XBB.1.5 variant as the other two vaccines. That variant was the dominant one in the U.S. earlier this year when the FDA had to choose the makeup of this fall's ...

The Novavax vaccine was one of the vaccines chosen for development as part of Operation Warp Speed. The U.S. government is providing $1.75 billion to the company to support the vaccine's development.

Novavax’s study involved nearly 30,000 people ages 18 and up in the U.S. and Mexico. Two-thirds received two doses of the vaccine, three weeks apart, and the rest got dummy shots.

Both mRNA vaccines have been tweaked to target the KP.2 strain of COVID-19, which is a slightly more recent version of the virus than what Novavax targets, which is KP.2's "parent" JN.1.